AbCellera Results Presentation Deck

Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 2 ANTIBODIES FOR COVID-19 There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone. bamlanivimab + etesevimab US shipments of bamlanivimab together with etesevimab halted in June because of the prevalence of resistant variants at the time (Gamma and Beta). Effective against Delta variant* bebtelovimab Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab. Effective against variants of concern, including the Delta variant* * Shown to be effective against the Delta variant in preclinical studies

View entire presentation